Hepatitis C and renal transplantation in era of new antiviral agents

doi:10.5500/wjt.v8.i4.84

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7489)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

434

WORD

225

HTML

3231

Figures (1-3)

194

Tables (1-6)

201

Sum=4285

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

500

Download

854

Sum=1354

Publishing Process of This Article

Item

Count

Browse

852

Download

998

Sum=1850

Aug 9, 2018 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Aug 9, 2018; 8(4): 84-96
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84

Open in New Tab Full Size Figure Download Figure

Figure 1 Hepatitis C virus infection is associated with an increased risk of renal disease, end-stage renal disease and renal-related mortality (REVEAL HCV Longitudinal Taiwanese study). HCV: Hepatitis C virus.

Open in New Tab Full Size Figure Download Figure

Figure 2 Development of new drugs for hepatitis C virus infection according the hepatitis C virus structure. HCV: Hepatitis C virus.

Open in New Tab Full Size Figure Download Figure

Figure 3 Sustained virological response with different therapies for hepatitis C virus genotype 1. HCV: Hepatitis C virus; SVR: Sustained virological response; IFN: Interferon; PEG IFN: Pegylated IFN; DAA: Direct acting antiviral; RBV: Ribavirin.

Citation: Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96
URL: https://www.wjgnet.com/2220-3230/full/v8/i4/84.htm
DOI: https://dx.doi.org/10.5500/wjt.v8.i4.84